Placebo News and Research

RSS

Novartis receives FDA approval for Flucelvax to prevent seasonal influenza

The U.S. Food and Drug Administration announced today the approval of Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of fertilized chicken eggs. Flucelvax is approved to prevent seasonal influenza in people ages 18 years and older.

21 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

19 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Personality traits linked with individual's susceptibility to placebo effect from pain medicines

Personality traits might do more than help you win a popularity contest. According to new University of Michigan-led neuroscience research, co-authored by University of Maryland (UM) School of Dentistry Dean Christian S. Stohler, DMD, DrMedDent, such traits also might make you more likely to get pain relief from a placebo - a fake medicine.

17 Nov 2012

Cinacalcet failure raises trial conduct issues

The oral calcimimetic agent, cinacalcet, has been found to have no significant effect on cardiovascular events or death in patients with chronic kidney disease in a randomized controlled trial.

16 Nov 2012

Hydrocortisone protects bilateral knee replacement patients

Repeat doses of corticosteroids may protect patients undergoing bilateral total knee arthroplasty from postoperative side effects such as fever, pain, and acute respiratory distress, research suggests.

16 Nov 2012

Oxytocin regulates social distance between women and men

Flirting brings women and men closer. But the "social distance" ensures that they will keep a certain spatial distance from each other. Researchers under the leadership of the University of Bonn studied whether this distance can be diminished by the so-called love hormone, oxytocin.

16 Nov 2012

Denosumab associated with improved overall survival in NSCLC patients

It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer (NSCLC) developing bone loss.

16 Nov 2012

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.

15 Nov 2012

Colon cancer risk: Supplements no substitute for dietary fiber

Dietary supplementation with resistant starch does not reduce long-term colorectal cancer risk in patients with Lynch syndrome, shows the CAPP2 study.

15 Nov 2012

NIH awards $4.1M grant to explore new ways for treating kidney stones

In the United States, one in 10 men and one in 14 women have had a kidney stone. Unless the kidney stone is too large to pass on its own, the treatment prescribed is usually plenty of fluids and painkillers while letting it pass over a period of several days.

15 Nov 2012

EU approves Forxiga for treatment of type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.

15 Nov 2012

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax's single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta.

15 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

Reflexology can help cancer patients manage their symptoms and perform daily tasks

A study led by a Michigan State University researcher offers the strongest evidence yet that reflexology - a type of specialized foot massage practiced since the age of pharaohs - can help cancer patients manage their symptoms and perform daily tasks.

14 Nov 2012

Tolvaptan improves kidney health in polycystic kidney disease

A vasopressin V2-receptor blocker slows the increase in total kidney volume and decline in kidney function in patients with autosomal dominant polycystic kidney disease, report US researchers.

12 Nov 2012

Multivitamin disappoints in first long-term CV trial

Taking a daily multivitamin does not reduce the risk for major cardiovascular events or mortality in men, research suggests.

9 Nov 2012

Placebo News and Research

Novartis receives FDA approval for Flucelvax to prevent seasonal influenza

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

GSK receives FDA approval for PROMACTA to treat thrombocytopenia

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Personality traits linked with individual's susceptibility to placebo effect from pain medicines

Cinacalcet failure raises trial conduct issues

Hydrocortisone protects bilateral knee replacement patients

Oxytocin regulates social distance between women and men

Denosumab associated with improved overall survival in NSCLC patients

RXi announces pharmacokinetic results from RXI-109 Phase 1 study in healthy subjects

Colon cancer risk: Supplements no substitute for dietary fiber

NIH awards $4.1M grant to explore new ways for treating kidney stones

EU approves Forxiga for treatment of type 2 diabetes

Paxvax PXVX0200 cholera vaccine demonstrates safety and immunogenicity in Phase 1 clinical trial

EpiCept third quarter revenue increases to $0.9 million

Reflexology can help cancer patients manage their symptoms and perform daily tasks

Tolvaptan improves kidney health in polycystic kidney disease

Multivitamin disappoints in first long-term CV trial

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News